

Disclosure of ToV made by Varnavas Hadjipanayis Ltd. representing Janssen Pharmaceuticals

Date of publication: 30/06/2016

	Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Unique country identifier OPTIONAL (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		TOTAL OPTIONAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
HCPs												
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	Dr Agathoclis Agathocleous	Nicosia	Cyprus	BOCOC		N/A	N/A	480	1018	Yearly amount	Yearly amount	
	Dr Stavros Stavrou	Nicosia	Cyprus	51, 28th October str, Strovolos		N/A	N/A	133	795	Yearly amount	Yearly amount	
	Dr. Ioannis Ntoupis	Athens	Greece	3, Thessalonikis str, Nikaia		N/A	N/A	Yearly amount	Yearly amount	1350	579	
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						N/A	N/A	912	1852	N/A	N/A	Optional
Number of Recipients in aggregate disclosure - Art. 3.02						N/A	N/A	1	1	N/A	N/A	Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						N/A	N/A	%	%	%	%	N/A
HCOs												
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	ΚΥΠΡΙΑΚΗ ΑΙΜΟΤΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ	ΛΕΥΚΩΣΙΑ	ΚΥΠΡΟΣ	ΠΑΛΑΙΟΣ ΔΡΟΜΟΣ ΛΕΥΚΩΣΙΑΣ-ΛΕΜΕΣΟΥ 215, 2029		Yearly amount	250	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
	ΠΑΓΚΥΠΡΙΟΣ ΣΥΝΔΕΣΜΟΣ ΝΟΣΗΛΕΥΤΩΝ ΚΑΙ ΜΑΙΩΝ	ΛΕΥΚΩΣΙΑ	ΚΥΠΡΟΣ	ΤΑΓΜΑΤΑΡΧΟΥ ΠΟΥΛΙΟΥ 1, ΔΙΑΜ. 101, 1101 ΛΕΥΚΩΣΙΑ		Yearly amount	250	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Optional
Number of Recipients in aggregate disclosure - Art. 3.02						number	number	number	number	number	number	Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						%	%	%	%	%	%	N/A
R & D												
AGGREGATE DISCLOSURE												
Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											TOTAL AMOUNT	OPTIONAL